These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 23332617)

  • 1. Vascular endothelial growth factor (VEGF-a) in Fabry disease: association with cutaneous and systemic manifestations with vascular involvement.
    Zampetti A; Gnarra M; Borsini W; Giurdanella F; Antuzzi D; Piras A; Smaldone C; Pieroni M; Cadeddu C; de Waure C; Feliciani C
    Cytokine; 2013 Mar; 61(3):933-9. PubMed ID: 23332617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anderson-Fabry disease: a multiorgan disease.
    Tuttolomondo A; Pecoraro R; Simonetta I; Miceli S; Pinto A; Licata G
    Curr Pharm Des; 2013; 19(33):5974-96. PubMed ID: 23448451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel α-galactosidase A mutation in patients with severe cardiac manifestations of Fabry disease.
    Duro G; Musumeci MB; Colomba P; Zizzo C; Albeggiani G; Mastromarino V; Volpe M; Autore C
    Gene; 2014 Feb; 535(2):365-9. PubMed ID: 24140492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Japanese patients with Fabry disease predominantly showing cardiac and neurological manifestation with novel missense mutation: R220P.
    Fukutomi M; Tanaka N; Uchinoumi H; Kanemoto M; Nakao F; Yamada J; Kamei T; Takenaka T; Fujii T
    J Cardiol; 2013 Jul; 62(1):63-9. PubMed ID: 23608164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phenotypical characterization of α-galactosidase A gene mutations identified in a large Fabry disease screening program in stroke in the young.
    De Brabander I; Yperzeele L; Ceuterick-De Groote C; Brouns R; Baker R; Belachew S; Delbecq J; De Keulenaer G; Dethy S; Eyskens F; Fumal A; Hemelsoet D; Hughes D; Jeangette S; Nuytten D; Redondo P; Sadzot B; Sindic C; Sheorajpanday R; Thijs V; Van Broeckhoven C; De Deyn PP
    Clin Neurol Neurosurg; 2013 Jul; 115(7):1088-93. PubMed ID: 23219219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The mutation p.D313Y is associated with organ manifestation in Fabry disease.
    du Moulin M; Koehn AF; Golsari A; Dulz S; Atiskova Y; Patten M; Münch J; Avanesov M; Ullrich K; Muschol N
    Clin Genet; 2017 Nov; 92(5):528-533. PubMed ID: 28276057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Fabry disease: clinic and enzymatic diagnosis of homozygous and heterozygous. New therapeutic prospects].
    Peces R; Olea T
    Nefrologia; 2002; 22(6):540-6. PubMed ID: 12516287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anderson-Fabry disease: developments in diagnosis and treatment.
    Kes VB; Cesarik M; Zavoreo I; Madzar Z; Demarin V
    Acta Clin Croat; 2012 Sep; 51(3):411-7. PubMed ID: 23330407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fabry disease.
    Schiffmann R
    Pharmacol Ther; 2009 Apr; 122(1):65-77. PubMed ID: 19318041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of serum vascular endothelial growth factor and nail fold capillaroscopy changes in systemic lupus erythematosus with and without cutaneous manifestations.
    Moneib HA; Salem SA; Aly DG; Khedr HT; Wafaey HA; Hassan HE
    J Dermatol; 2012 Jan; 39(1):52-7. PubMed ID: 21950586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disease manifestations and X inactivation in heterozygous females with Fabry disease.
    Maier EM; Osterrieder S; Whybra C; Ries M; Gal A; Beck M; Roscher AA; Muntau AC
    Acta Paediatr Suppl; 2006 Apr; 95(451):30-8. PubMed ID: 16720462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Globotriaosylceramide induces lysosomal degradation of endothelial KCa3.1 in fabry disease.
    Choi S; Kim JA; Na HY; Cho SE; Park S; Jung SC; Suh SH
    Arterioscler Thromb Vasc Biol; 2014 Jan; 34(1):81-9. PubMed ID: 24158513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional and structural nerve fiber findings in heterozygote patients with Fabry disease.
    Torvin Møller A; Winther Bach F; Feldt-Rasmussen U; Rasmussen A; Hasholt L; Lan H; Sommer C; Kølvraa S; Ballegaard M; Staehelin Jensen T
    Pain; 2009 Sep; 145(1-2):237-45. PubMed ID: 19665302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical spectrum of Anderson Fabry disease in a Romanian family.
    Tudor A; Muşat A; Doscan A; Bari M; Zapucioiu C; Urdea E; Cochior D; Peţa D
    Rom J Intern Med; 2006; 44(2):201-10. PubMed ID: 17236300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma globotriaosylsphingosine (lysoGb3) could be a biomarker for Fabry disease with a Chinese hotspot late-onset mutation (IVS4+919G>A).
    Liao HC; Huang YH; Chen YJ; Kao SM; Lin HY; Huang CK; Liu HC; Hsu TR; Lin SP; Yang CF; Fann CS; Chiu PC; Hsieh KS; Fu YC; Ke YY; Lin CY; Tsai FJ; Wang CH; Chao MC; Yu WC; Chiang CC; Niu DM
    Clin Chim Acta; 2013 Nov; 426():114-20. PubMed ID: 24055776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fabry disease in patients with end-stage renal failure: the potential benefits of screening.
    Bekri S; Enica A; Ghafari T; Plaza G; Champenois I; Choukroun G; Unwin R; Jaeger P
    Nephron Clin Pract; 2005; 101(1):c33-8. PubMed ID: 15886492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma globotriaosylsphingosine as a biomarker of Fabry disease.
    Togawa T; Kodama T; Suzuki T; Sugawara K; Tsukimura T; Ohashi T; Ishige N; Suzuki K; Kitagawa T; Sakuraba H
    Mol Genet Metab; 2010 Jul; 100(3):257-61. PubMed ID: 20409739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Evaluation of patients with Fabry disease in Argentina].
    AADELFA (Asociación Argentina de estudio de enfermedad de Fabry y otras enfermedades lisosomales)
    Medicina (B Aires); 2010; 70(1):37-43. PubMed ID: 20228022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pediatric Fabry disease.
    Ries M; Gupta S; Moore DF; Sachdev V; Quirk JM; Murray GJ; Rosing DR; Robinson C; Schaefer E; Gal A; Dambrosia JM; Garman SC; Brady RO; Schiffmann R
    Pediatrics; 2005 Mar; 115(3):e344-55. PubMed ID: 15713906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Molecular pathology and clinical manifestations of Fabry disease].
    Rákóczi E; Görögh S; Grubits J; Erdos M; Garzuly F; Hahn K; Bencsik K; Vécsei L; Trinn C; Kristóf E; Mogyorósy G; Tóth B; Maródi L
    Orv Hetil; 2007 Jun; 148(23):1087-94. PubMed ID: 17545117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.